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Edited by Miguel De la RosaAbstract The Eyes Absent (Eya) proteins are tyrosine phospha-
tases and transcriptional activators involved in cell-fate determi-
nation and organ development. Mutations in the gene encoding
Eya homologue 1 have been implicated in the multi-organ devel-
opmental disorder branchio-oto-renal syndrome (BOR) and in
ocular defects. Here we report that BOR-associated mutations
lead to a loss of phosphatase activity in Eya1 proteins, while
mutations associated with ocular defects yield Eya1 proteins with
near normal levels of phosphatase activity. Furthermore we dem-
onstrate that the N-terminal domain attenuates the catalytic
activity of Eya suggesting a mechanism of regulation.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Tyrosine phosphatase; Eyes Absent; Eya; Eye
development; Branchio-oto-renal syndrome1. Introduction
Branchio-oto-renal (BOR) or Melnick-Fraser syndrome is
an autosomal dominant disorder characterized by branchial
cysts, ear malformations, hearing loss, and renal anomalies.
The related branchio-oto syndrome (BO) has only branchial
and otic anomalies. The gene responsible for BOR is a mam-
malian homologue (EYA1) of the Drosophila Eyes Absent
(eya) gene [1]. EYA1 mutations are also associated with con-
genital cataracts and ocular segment anomalies [2].
Eya genes are commonly co-expressed with Pax, Six/sine
oculis (SO), and Dachshund (Dach/Dac) genes, which together
form the retinal determination cascade (named after its initial
description in Drosophila eye development [3]). There are four
mammalian Eya homologues, Eya1–4. Eya1 controls signaling
events involved in early kidney and ear development and mice
heterozygous for Eya1 exhibit renal abnormalities and conduc-Abbreviations: Eya, Eyes Absent; ED, conserved C-terminal Eyes
Absent domain; BOR, branchio-oto-renal syndrome; BO, branchio-
oto syndrome; SO, sine oculis; Dach/Dac, Dachshund; pNPP, p-nitro
phenyl phosphate; MBP, maltose binding protein; GST, glutathione
S-transferase; MyBP, myelin basic protein; HAD, haloacid dehalo-
genase; pY, phosphotyrosine; pS, phosphoserine; pT, phosphothreo-
nine; PTP, protein tyrosine phosphatase
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doi:10.1016/j.febslet.2006.06.009tive hearing loss, while Eya1 homozygotes entirely lack ears
and kidneys [4], correlating well with the assignment of Eya1
as the gene responsible for BOR syndrome. However, although
the existence of Eya1 mutations associated with ocular defects
suggests a role in eye development, Eya1 knockout mice have
no reported ocular defects. The majority of disease-associated
missense mutations cluster in the conserved C-terminal 271-
residue Eya domain (ED) of Eya [5]. This domain has tyrosine
phosphatase activity [6–8] and participates in interactions with
SO/SIX [9–11], DAC/DACH [9], and hetero-trimeric G pro-
teins [12,13]. The N-terminal domain of Eya is poorly con-
served and can transactivate when fused with, or bound to, a
DNA-binding protein [10,14].
BOR-associated mutations are known to disrupt protein–
protein interactions with Six, Dach, Ga2, and Gai2 proteins
[15,16]. Here we show that BOR-associated mutations result
in a loss of Eya1 phosphatase activity, while mutations associ-
ated with cataracts and ocular defects do not. We also show
that the phosphatase activity of the full-length Eya protein is
signiﬁcantly lower than that of the isolated ED domain, sug-
gesting the existence of a regulatory mechanism.2. Materials and methods
2.1. Materials
pGEX-4T from Pharmacia. pMAL, tyrosine and serine/threonine
assay kit using myelin basic protein (MyBP) as a substrate, and PP1
were obtained from New England Biolabs (NEB). Phosphopeptides
and malachite green reagent were purchased from Upstate Biotechnol-
ogy. p-nitro phenyl phosphate (pNPP) was from Sigma.
2.2. Recombinant proteins
Recombinant proteins described here, except maltose binding pro-
tein (MBP)-tagged full length Eya3 were produced in Escherichia
coli strain BL21(DE3) as glutathione S-transferase (GST)-fusions
using the overexpression vector pGEX-4T. Amino acid substitutions
were introduced by PCR mutagenesis. The catalytic domain of
PTP1B (residues 1–321) was inserted into pGEX-4T from a template
kindly provided by Dr. Z.-Y. Zhang (Albert Einstein College of
Medicine). The proteins were puriﬁed by aﬃnity chromatography
with glutathione-agarose, the GST-tag cleaved with thrombin and
the resulting proteins further puriﬁed by size exclusion chromatogra-
phy on a Superdex-75 column. MBP-tagged Eya3 was produced in
BL21(DE3) using the vector pMAL and puriﬁed by amylose-aﬃnity
chromatography.
2.3. Phosphatase assays
Phosphatase assays for all Eya proteins using pNPP, phospho-ami-
no-acids, phosphopeptides or MyBP as substrates were conducted as
described previously [17]. Unless speciﬁcally stated otherwise theblished by Elsevier B.V. All rights reserved.
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published reaction conditions were used for PTP1B [18]. PP1 assays
followed the protocol described in the PSP assay system by NEB.3. Results
3.1. Phosphatase activity of Eya1
A basic biochemical characterization of the catalytic domain
of mouse Eya1 (residues 319–591) was ﬁrst conducted, expand-
ing on our initial report that this domain has signiﬁcant phos-
phatase activity [6,17]. At pH 6 and in the presence of 20 mM
Mg2+ Eya1(ED) yielded the parameters kcat = 56 s
1 and
Km = 1.8 mM towards the model substrate pNPP (Fig. 1a).
As in the case of previously characterized Eya proteins [6,17]
the phosphatase activity of Eya1(ED) required divalent cations
and was greatest between pH 5 and 6 (Fig. 1b). Based upon
these standardization studies, we proceeded to measure the
phosphatase activity of various disease-associated mutation-
ally altered forms.
3.2. Phosphatase activity of BOR associated mutations of Eya1
A Serﬁ Pro substitution at codon 487 and a Leuﬁ Arg
substitution at codon 505 of human EYA1 have been reported
in BOR-aﬀected patients [5]. Leu505 is conserved in all Eya
proteins, and Ser487 is conserved among Eya1, Eya4, and Dro-
sophila Eya. Both mutations were introduced into the codingFig. 1. Characterization of the phosphatase activity of Eya1(ED).
(a) Hydrolysis of pNPP by Eya1(ED) follows Michaelis–Menten
kinetics. The reaction was conducted at pH 6 in the presence of 20 mM
MgCl2. (b) pH dependence of pNPP hydrolysis by Eya1(ED). The A410
values plotted on the y-axis measure the amount of product (p-
nitrophenol) formed. The experiments were conducted under identical
conditions of protein and substrate concentration, divalent ion and salt
concentration. pH was altered by using the buﬀers Na-acetate for pH
4.5–5, MES for pH 5.5–6.5, Tris for pH 7–8.5.sequence for mouse Eya1(ED) yielding S486P and L504R. Hu-
man EYA1 and mouse Eya1 sequences are 98.7% identical,
with 99.6% identity in the ED domain, making the mouse pro-
tein a suitable model for the human protein. The phosphatase
activity was measured on pNPP and on a tyrosine-phosphory-
lated peptide (RRLIEDAEpYAARG) derived from Src and
previously shown to be a good model Eya substrate [6]. Both
mutations resulted in severely reduced catalytic activity
(Fig. 2a), suggesting that compromised phosphatase activity
may contribute to the developmental defects observed in
BOR syndrome patients.
3.3. Phosphatase activity of Eya1 mutants associated with ocular
defects
Three EYA1 missense mutations, encoding for the amino-
acid substitutions E363K, R547G and G426S have been iden-
tiﬁed in patients with anomalies of anterior eye segments [2].
The corresponding residues in mouse Eya1 are E362, R546
and G425. Glu362 and Gly425 are conserved among all animal
Eya homologues. Arg546 is present in Eya1 and Eya2, Eya3
has a Lys at this position, while Eya4 has a Thr. The patient
with the G426S substitution had renal and otic anomalies in
addition to cataracts, thus representing an atypical case of
BOR syndrome. Eya1(ED)R546G and Eya1(ED)G425S re-
tained phosphatase activity, with the G425S substitution
resulting in consistently higher activity than the wild-type
protein (Fig. 2a).
We were unable to generate suﬃcient pure, recombinant
Eya1(ED)E362K to conduct assays, so the corresponding
mutation (E281K) was introduced in Eya3(ED). Eya1(ED)
and Eya3(ED) share 68% sequence identity (Fig. 5a).
Eya3(ED) has been well characterized and shown to have
strong phosphatase activity towards tyrosine phosphorylated
substrates [6]. Eya3(ED)E281K retained near wild-type cata-
lytic activity (Fig. 2b). Taken together the data on
Eya1(R546G) and Eya3(E281K) suggest that these ocular de-
fects are not associated with the loss of Eya’s phosphatase
activity. This observation is in agreement with a recent report
[19] that mutations associated with ocular defects, when intro-
duced into Drosophila eya, do not reduce its ability to induce
ectopic eye formation or to rescue the eya2 null phenotype
(the eye-speciﬁc null allele eya2 lacks all eye tissue).
3.4. The phosphatase activity of Eya3 mutants
To establish whether introducing analogous amino acid sub-
stitutions in Eya1 and Eya3 similarly aﬀected the catalytic
activities of the two proteins we assayed Eya3(ED) bearing
the substitutions L423R (homologous to L504R in Eya1),
G344S (homologous to G425S in Eya1) and K465G (homolo-
gous to R546G in Eya1). Eya3(ED)K465G retained phospha-
tase activity while Eya3(ED)G344S and L423R had
substantially reduced activity (Fig. 2b). The results with
K465G and L423R parallel those obtained for similar substitu-
tions in Eya1. However the loss of catalytic activity for
Eya3(ED)G344S is in stark contrast with the strong activity re-
tained by Eya1(ED)G425S.
Mutsuddi et al. [19] have reported the eﬀect of BOR- and
ocular defect-associated mutations on the phosphatase activity
of the GST-fusion form of Eya3(ED). Except for GST-
Eya3(ED)G344S, all substitutions (L423R, K465G, E281K)
resulted in either undetectable or unmeasurable activity.
A major diﬀerence between our experiments and those of
Fig. 2. BOR-associated amino acid substitutions lead to a loss of phosphatase activity. (a) The phosphatase activity of BOR and ocular-defect
associated amino acid substitutions on the phosphatase activity of (a) Eya1(ED) and (b) Eya3(ED) are indicated. Gray bars show the activity
towards pNPP and black bars show activity towards the tyrosine-phosphorylated Src-derived peptide RRLIEDAEpYAARG. In panel (a) the
activity of Eya1(ED) towards each substrate is used as the reference and the activities of the mutationally altered forms are indicated as a percentage
relative to Eya1(ED). Similarly in panel (b) the activity of Eya3(ED) is used as the reference.
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the protein. Eya3(ED) yields kcat towards pNPP of 1065 s
1[6],
which is nearly 7 orders of magnitude greater than that re-
ported for GST-Eya3(ED) (kcat = 0.017 min
1) [8]. Thus the
activity of the recombinant proteins used by Mutsuddi et al.
is extremely low, making even small reductions in activity
undetectable. In our hands GST-Eya3(ED) was 27% as active
as untagged Eya3(ED) on a pNPP substrate under identical
experimental conditions. Several mechanisms could account
for this observation; the GST moiety could occlude the active
site, GST could alter the conformation of the ED domain or
GST-induced dimerization could result in a change in active
site accessibility. GST is known to dimerize, hence GST-fu-
sions often result in non-physiological dimers [20,21]. Interest-
ingly, Drosophila EYA has been shown to self-associate [22],
and Li et al. have previously reported that full-length GST-
Eya3 has a signiﬁcantly lower kcat (0.074 s
1) [7] than that
measured for Eya3(ED) with a pNPP substrate [6]. Taken to-
gether these observations led us to speculate that perhaps olig-
omerization (whether intrinsic or GST-mediated) can
attenuate catalytic activity. In order to test the possibility that
the presence of the N-terminal domain modulates the phos-
phatase activity of Eya3, we generated Eya3 protein constructs
that included the catalytic ED domain with varying portions of
the N-terminal domain (Fig. 3) and measured the phosphatase
activity of each construct towards pNPP, phosphotyrosine
(pY), phosphoserine (pS), phosphothreonine (pT) and MyBP
that has been either tyrosine or ser/thr phosphorylated. We
are not able to obtain soluble, puriﬁed, untagged full-length
Eya3 in quantities suﬃcient to perform these assays and so
we used an N-terminal fusion of Eya3 to MBP. Eya3(238–510), Eya3(223–510), and Eya3(194–510) had comparable
phosphatase activities and a clear preference for tyrosine-phos-
phorylated substrates (Figs. 3 and 4). On the other hand
Eya3(179–510), Eya3(45–510) and full-length Eya3 had signif-
icantly reduced phosphatase activity overall and showed no
marked selectivity between tyrosine, serine- or threonine-phos-
phorylated substrates (Figs. 3 and 4), similar to the results pre-
viously reported for GST-Eya3 [7]. To provide a context in
which the speciﬁcity data could be interpreted we conducted
selected control assays with well-studied phosphatases. The
tyrosine phosphatase PTP1B had less than 9% activity towards
pS/pT relative to its activity towards pY. The Ser/Thr phos-
phatase PP1 had less than 24% activity towards pY-MyBP rel-
ative to its activity towards pS/T-MyBP. The degree of
speciﬁcity exhibited by these enzymes towards their preferred
substrates is similar to that shown by Eya3 constructs lacking
residues N-terminal to 194.
3.5. Homology model of Eya1(ED)
Eya proteins are phosphatases belonging to the haloacid
dehalogenase (HAD) structural family [6–8,17]. However, se-
quence homology between the Eya catalytic domain and other
members of the HAD family is restricted to the three con-
served motifs shown in Fig. 3. Sequence alignment with
HAD enzymes of known structure (as classiﬁed by [23]) places
the Eya catalytic domain in subclass I, i.e. it has a large in-
serted domain between motifs I and II. Using the fold recogni-
tion program LOOPP [24,25], which uses a combination of
sequence alignment, threading, secondary structure and ex-
posed surface area predictions to identify template structures,
L-2-HAD (1ZRN.PDB [26]) was found to be a good model for
Fig. 4. Substrate speciﬁcity of Eya3. (a) Activity of various Eya3 constructs towards pY, pS and pT relative to the activity of Eya3(ED) towards pY.
The relative activity of the classical tyrosine phosphatase PTP1B towards pY, pS and pT is in the inset. (b) Relative phosphatase activity of various
Eya3 constructs towards either tyrosine-phosphorylated MyBP or Ser/Thr-phosphorylated MyBP. Activity of Eya3(ED) is the reference set at 100%.
Phosphatase activities of the tyrosine phosphatase PTP1B and a well-studied Ser/Thr phosphatase PP1 were measured in parallel experiments and the
results are inset.
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Fig. 3. Catalytic activity of various deletion constructs of Eya3 towards pNPP and pY. The left panel is a schematic representation of the constructs
tested. The location of the three conserved motifs found in all HAD enzymes are indicated in each construct by ﬁlled boxes and the sequences are
shown. Upper case, bold letters indicate residues in common between Eya proteins and the HAD enzymes, and the lower case letters are present only
in Eya3. Catalytic parameters for each of the constructs are shown on the right. Asterisk indicates previously reported parameters [6].
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a/b hydrolase domain found in all HAD enzymes. A separate
alignment of the sequences of L-2-HAD and Eya1(ED) by do-
main ﬁshing using 3DJIGSAW [27] lined up residues 321–343
of Eya1 with the N-terminal sequence of L-2-HAD such thatHAD motif I of both proteins were aligned. Based on these
alignments (Fig. 5a) a three-dimensional model for residues
321–591 of Eya1 was built by the program 3DJIGSAW
(Fig. 5b). This model does not include residues 344–422, which
are part of the capping inserted domain.
Fig. 5. Structural model for the ED domain of Eya1. (a) Sequences of Eya1(ED) and Eya3(ED) aligned with L-2-HAD that was used as a template
for homology modeling. Blue shading indicates sequence similarity among the Eya proteins. Black outline indicates the region of Eya1(ED) included
in the model shown in (b). Black arrowheads indicate Eya1(ED) amino acid substitutions associated with BOR and ocular defects. The red lines
indicate conserved motifs characteristic of HAD family proteins. (b) Ca trace of the Eya1(ED) model shown as a ribbon generated by GRASP [32].
Residues associated with either BOR or ocular defects are indicated. Location of amino acid substitutions that result in a loss of phosphatase activity
are in blue and those that do not reduce phosphatase activity in cyan. Red backbone represents conserved sequence motifs as in (a). Black dashed line
indicates residues 344–422 that are not modeled.
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The Eya proteins are multi-functional, hence mutations in
the Eya1 gene can contribute to disease states through several
biochemical mechanisms. Here we have shown that BOR-asso-
ciated mutations in Eya1 result in signiﬁcantly reduced tyro-
sine phosphatase activity. By contrast, a mutation associated
with ocular defects and BOR syndrome and those associated
only with ocular defects retained phosphatase activity. Inter-
estingly, none of these ocular defect associated substitutions
severely compromise known Eya1 protein–protein interactions
or its transactivation potential [15,16], suggesting that they
aﬀect an as-yet-undeﬁned activity of Eya1.
In order to probe the structural basis for these observations
we generated a three-dimensional homology model of
Eya1(ED) (Fig. 5). While the sequence similarity between
Eya1(ED) and the template L-2-HAD is low (17% sequence
identity and 41% similarity), homology models have been suc-
cessfully built for other HAD phosphatases using similar ap-proaches [28], and a model for the ED domain of Drosophila
Eya using another HAD family enzyme (phosphonoacetalde-
hyde hydrolase) as a template has been reported [8]. The struc-
tural model of Eya1(ED) consists of two domains, an a/b
domain that adopts a Rossman fold and a helical domain in-
serted after the ﬁrst b-strand of the a/b domain. The residues
corresponding to the three conserved motifs are at the inter-
face of these domains. Missing from this model is a region
of 79 residues of the inserted domain for which we could not
ﬁnd a suitable structural template.
None of the amino acid substitutions associated with either
BOR/BO or ocular defects are within a signature HAD motif.
The R546G and E362K substitutions, both associated with
ocular defects, are distant from the active site; Arg546 is on
a surface loop while Glu362 is in the inserted region not mod-
eled in Fig. 5a. Substitutions at these locations do not ad-
versely aﬀect the phosphatase activity. Residue Gly425 is
immediately adjacent to the 79-residue inserted domain that
we were unable to model. Furthermore, Gly425 is adjacent
3858 J.P. Rayapureddi, R.S. Hegde / FEBS Letters 580 (2006) 3853–3859to a region of poor homology between Eya1 and Eya3 suggest-
ing that the three-dimensional structures of Eya3 and Eya1
might diﬀer around this residue. This would be in keeping with
the observation that replacement of Gly425 with a Ser diﬀeren-
tially aﬀects the phosphatase activities of Eya1(ED) and
Eya3(ED).
Substitutions associated with BOR syndrome are located in
structurally critical regions of the Eya1(ED) model. The
backbone nitrogen of Ser486 forms hydrogen bonds with the
backbone oxygens of residues 483 and 484 stabilizing the sec-
ondary structure of the protein. A proline would be unable to
form such hydrogen bonds aﬀecting structural stability hence
the severely reduced phosphatase activity reported for
Eya1(ED)S486P. The side-chain of Leu504 is solvent-exposed
and at the interface between the hydrolase and capping
domains. Thus the L504R substitution could alter both the
surface properties and protein conformation. Interestingly, a
previous report suggests that Eya1 bearing the S486P or
L504R substitutions was impaired in its ability to interact with
Dach/Dac, Six and G proteins, and the protease digestion pro-
ﬁles of these altered Eya1 proteins are distinct from that of the
wild-type protein [16]. Together the data suggest that these
BOR-associated substitutions eﬀect a global conformational
alteration in the protein and have an impact upon multiple
activities.
Phosphatase-deﬁcient Eya proteins function poorly in ﬂy eye
development [6,8] and in the control of cell growth and prolif-
eration [7], underscoring the biological relevance of the phos-
phatase activity. Yet our data shows that the presence of the
N-terminal domain (as in the full-length protein) signiﬁcantly
attenuates the phosphatase activity of Eya3. It has been previ-
ously proposed that the ED domain of Eya acts as an auto-
inhibitor of the transactivation potential of the N-terminal
domain [22]. Taken together the evidence would support a
model where unmasking the phosphatase and transactivating
activities of Eya might require a conformational change, likely
mediated by cofactor binding. Another possibility is that the
activities are regulated by the oligomerization state of the pro-
tein; Drosophila EYA has been shown to dimerize [22] and we
show here that the presence of an artiﬁcial dimerization-medi-
ator (the GST-tag) leads to a reduction in phosphatase activity
of Eya3(ED). There is precedent for an oligomerization-medi-
ated regulatory mechanism among the classical (thiol-based)
protein tyrosine phosphatases (PTPs); both receptor PTPs
such as CD45 [29,30], and non-receptor PTPs such as epsilon
[31], are regulated by dimerization. The physiological signals
that regulate the oligomeric state and/or the catalytic activity
of Eya remain to be investigated. Obvious candidates are inter-
actions with the Six or Dach/Dac proteins, but other yet
unidentiﬁed binding partners may well play a role.
In summary, the results presented here demonstrate that
mutations associated with BOR syndrome result in severely re-
duced phosphatase activity of Eya1 while mutations associated
with ocular defects do not compromise the phosphatase activ-
ity of Eya1. Furthermore we show that full-length Eya has
lower phosphatase activity than the isolated catalytic ED do-
main, suggesting a possible mechanism for the physiological
regulation of Eya.Acknowledgements: We thank C. Kattamuri for help in protein puriﬁ-
cation and G. Nimako for technical assistance. This work was sup-
ported by the National Institutes of Health Grant EY014648.References
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